Pulmonology

Reports of high-impact pulmonology studies by medical professionals

Pembrolizumab plus concurrent chemoradiation therapy associated with robust antitumor activity in patients with locally...

1. Concomitant pembrolizumab plus chemoradiation therapy was associated with improved antitumor activity and safety profile in patients with previously untreated, locally advanced, stage III...

Randomized trial of plant-derived vaccine for COVID-19

1. A plant-derived, virus-like particle displays the SARS-CoV-2 spike glycoprotein and appears to be a promising candidate for a vaccine. 2. Adverse outcomes were mild-to-moderate,...

Critically ill COVID-19 patients in Africa may have worse outcomes compared to global rates...

1. In-hospital mortality within 30 days of admission for COVID-19 was 48% (vs. global mortality 31.5%). 2. Increased age, underlying comorbidities and delay in admission...

Dexamethasone vs methylprednisolone high dose for COVID-19 pneumonia

1. Hospitalized COVID-19 patients receiving high-dose methylprednisolone followed by oral prednisone had improved clinical outcomes compared to patients receiving dexamethasone. Evidence Rating Level: 2 (Good) In...

Tezepelumab reduced annual exacerbation rates in patients with severe asthma

1. Subcutaneous tezepelumab treatment reduced the rate of annual asthma exacerbations in patients with severe asthma compared to the placebo group. 2. No significant differences...

BNT162b2 mRNA vaccine shows benefit against symptomatic and asymptomatic SARS-CoV-2 infection 

1. Vaccinated individuals reported fewer SARS-CoV-2 infections and a lesser proportion of cases were symptomatic compared to the unvaccinated cohort. 2. BNT162b2 mRNA vaccine showed...

Delayed antibiotic prescribing is a safe and effective for respiratory tract infections in a...

1. There was no difference in follow-up symptom severity between patients who received immediate or delayed antibiotics for respiratory tract infections. 2. Delaying antibiotics was...

Tocilizumab may improve survival in COVID-19 patients with hypoxia and systemic inflammation 

1. Compared to usual care, fewer patients in the tocilizumab group died within 28 days of randomization. 2. Patients allocated tocilizumab were more likely to...

Rifapentine-moxifloxacin noninferior to standard of care treatment for pulmonary tuberculosis

1. Rifapentine-moxifloxacin treatment was shown to be non-inferior compared to standard therapy for tuberculosis. 2. Rifapentine without moxifloxacin treatment was shown to be inferior to...

Vulnerability of Never-Smoking Youth to Cigarette Smoking and Tobacco Industry Marketing

1. In a large and diverse cohort study, multiple susceptibility factors accurately predicted smoking outcomes 4 years later.  2. Exposure to tobacco marketing and electronic...

All-time hits